<Insert Hospital/Clinic Name>

<Insert hospital/clinic name>

now offers a breakthrough technology that improves detection of bladder cancer

Blue-Light Cystoscopy with Cysview® is an innovative technology that has been clinically proven to increase the detection of bladder cancer.* Cysview (hexaminolevulinate HCl) uses a special solution and a blue light that

work together to highlight hard-to-see tumors so that doctors can remove them.

Used together with the traditional white-light method,

Blue-Light Cystoscopy with Cysview:

Improves detection*―so that your doctor can see and remove

more cancerous tumors

Allows better disease management―by removing more tumors

To learn more, go to

Bladder image of hard-to-see tumor using white-light cystoscopy

Same bladder image showing tumor when using Blue-Light Cystoscopy with Cysview

Ask your doctor if Blue-Light Cystoscopy with Cysview would be right for you

<Space for hospital/clinic/urologist info>

*Source: Cysview prescribing information.

Product Indication

Cysview is an optical imaging agent indicated for use in the cystoscopic detection of nonmuscle invasive papillary bladder cancer (NMIBC) among patients suspected or known to have lesion(s) on the basis of a prior cystoscopy. Cysview is used with the KARL STORZ D-Light C Photodynamic Diagnostic (PDD) System to perform cystoscopy with the blue-light setting (Mode 2) as an adjunct to the white-light setting (Mode 1).

Important limitations of use: Cysview is not a replacement for random bladder biopsies or other procedures used in the detection of bladder cancer and is not for repetitive use.

Important Risk and Safety Information

Cysview is not a replacement for random bladder biopsies or other procedures used in the detection of bladder cancer and is not for repetitive use.

Anaphylaxis reactions including anaphylactoid shock, hypersensitivity reactions, bladder pain, cystitis, and abnormal urinalysis have been reported after administration of Cysview. The most common adverse reactions seen in clinical trials were bladder spasm, dysuria, hematuria, and bladder pain.

Cysview should not be used in patients with porphyria, gross hematuria, or with known hypersensitivity to hexaminolevulinate, or in patients receiving intravesical chemotherapy or BCG treatment within 3 months of Cysview photodynamic blue-light cystoscopy. There are no known drug interactions with hexaminolevulinate; however, no specific drug interaction studies have been performed. Using Cysview, fluorescence of non-malignant areas may occur, and Cysview may fail to detect some malignant lesions.

Safety and effectiveness have not been established in pediatric patients. Cysview should only be used during pregnancy if the potential benefit justifies the potential risk to the fetus. It is not known whether hexaminolevulinate is excreted in human milk. Because many drugs are excreted in human milk, exercise caution when Cysview is administered to nursing mothers. No clinically important differences in safety or efficacy have been observed between older and younger patients.

Cysview is approved for use with the Karl Storz D-Light C Photodynamic Diagnostic (PDD) system. For system set up and general information for the safe use of the PDD system, please refer to the Karl Storz instruction manuals for each of the components.

Prior to Cysview administration, read the Full Prescribing Information and follow the preparation and reconstitution instructions.

© 2012 Photocure Inc. All rights reserved.

Cysview is a registered trademark of Photocure ASA. October 2012 CYSC2012024